Literature DB >> 24290896

Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India.

Partha Sarathi Biswas1, Devosri Sen2, Raghabes Majumdar3.   

Abstract

OBJECTIVES: Serious adverse effects such as acute psychoses have been reported following treatment with chloroquine. Chloroquine can cause cell death, including neurons. We aimed to identify the most frequent type of psychiatric manifestation and symptomatological characteristics of psychosis following chloroquine ingestion (PFC).
METHOD: Out of a total of 4471 randomly selected recent-onset psychosis patients, 3610 consecutive patients who had responded to standard treatment were screened for entry in the study. We compared background clinicodemographic profile information and psychopathology of 51 PFC patients, who were either drug free or drug naive, to 51 brief psychotic disorder (BPD) patients who were matched in terms of age, sex and education. Only those patients who remitted within 8 weeks (PFC patients) or 4 weeks (BPD patients) were included. Cranial computed tomography, electroencephalography and lumbar puncture of the entire experimental group were normal, and none had Mini Mental Status Examination score <22. Group difference and correlational statistics (parametric and nonparametric) have been used to test the hypotheses and explain the results.
RESULTS: The most common (76.2%) type of psychiatric disturbance in PCF group was mood disorder (mixed episode) accompanied by predominant irritability with little blunting of affect. PFC patients characteristically had prominent positive symptoms with visual hallucination and derealization experiences. They were more restless, agitated and anxious and had more disturbed thought content and orientation, but better preserved insight. There was no linear relationship between the amount of chloroquine consumed and the severity of psychosis.
CONCLUSION: Considering the large number of patients still receiving chloroquine especially in developing countries, this study has been presented to draw attention of the psychiatrists and other health professionals to the hazardous effect of chloroquine on mental health.
© 2013.

Entities:  

Keywords:  Brief psychotic disorder; Chloroquine-induced psychosis; Organic psychosis; Substance-induced; Toxic psychoses

Mesh:

Substances:

Year:  2013        PMID: 24290896     DOI: 10.1016/j.genhosppsych.2013.07.012

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  8 in total

Review 1.  Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Authors:  Sergio Marin; Alba Martin Val; Maite Bosch Peligero; Cristina Rodríguez-Bernuz; Ariadna Pérez-Ricart; Laia Vilaró Jaques; Roger Paredes; Josep Roca; Carles Quiñones
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-21

Review 2.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

3.  Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy.

Authors:  Nicole M Maxwell; Remington L Nevin; Stephen Stahl; Jerald Block; Sarah Shugarts; Alan H B Wu; Stephen Dominy; Miguel Alonso Solano-Blanco; Sharon Kappelman-Culver; Christopher Lee-Messer; Jose Maldonado; Andrew J Maxwell
Journal:  Clin Case Rep       Date:  2015-04-09

4.  Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.

Authors:  Mary A Bitta; Symon M Kariuki; Clifford Mwita; Samson Gwer; Leah Mwai; Charles R J C Newton
Journal:  Wellcome Open Res       Date:  2017-06-02

5.  Psychosis consequent to antimalarial drug use in a young child.

Authors:  Jitender Aneja; Dheeraj Goya; Bharat Choudhary
Journal:  J Family Med Prim Care       Date:  2019-05

6.  Chloroquine-Induced First-Episode Psychosis in a Patient Self-medicated for COVID-19.

Authors:  Marine Ambar Akkaoui; Michel Lejoyeux; Pierre A Geoffroy
Journal:  Biol Psychiatry       Date:  2020-06-02       Impact factor: 13.382

7.  Remitting neuropsychiatric symptoms in COVID-19 patients: Viral cause or drug effect?

Authors:  David A Forero-Peña; Matthew M Hernandez; Iriana Paola Mozo Herrera; Iván Bolívar Collado Espinal; Joselyn Páez Paz; Carlos Ferro; David M Flora-Noda; Andrea L Maricuto; Viledy L Velásquez; Natasha A Camejo-Avila; Emilia M Sordillo; Lourdes A Delgado-Noguera; Luis A Perez-Garcia; Carlos G Morantes Rodríguez; María Eugenia Landaeta; Alberto E Paniz-Mondolfi
Journal:  J Med Virol       Date:  2021-11-19       Impact factor: 20.693

8.  Psychiatric side effects of chloroquine in COVID-19 patients: two case reports.

Authors:  Roukaya Benjelloun; Yassine Otheman; Chafik El Kettani
Journal:  Pan Afr Med J       Date:  2020-06-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.